HC Wainwright & Co. Maintains Buy on Zevra Therapeutics, Raises Price Target to $18
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has maintained its Buy rating on Zevra Therapeutics (NASDAQ:ZVRA) and raised the price target from $15 to $18.
August 05, 2024 | 10:41 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating on Zevra Therapeutics and raised the price target from $15 to $18.
The Buy rating and increased price target from a reputable analyst firm like HC Wainwright & Co. is likely to positively impact investor sentiment and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100